Last Price
16.70
Today's Change
+0.22 (1.33%)
Day's Change
16.329 - 16.90
Trading Volume
332,563
Market Cap
2 Billion
Shares Outstanding
123 Million
Avg Volume
545,933
Avg Price (50 Days)
13.98
Avg Price (200 Days)
12.99
PE Ratio
15.32
EPS
1.09
Earnings Announcement
25-Aug-2025
Previous Close
16.48
Open
16.65
Day's Range
16.33 - 16.9
Year Range
8.61 - 19.77
Trading Volume
332,563
1 Day Change
1.33%
5 Day Change
7.19%
1 Month Change
17.61%
3 Month Change
44.46%
6 Month Change
15.73%
Ytd Change
36.33%
1 Year Change
-15.91%
3 Year Change
196.10%
5 Year Change
1165.15%
10 Year Change
838.20%
Max Change
192.47%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.